Tonix Pharmaceuticals
David Hsu has extensive experience in clinical science and psychiatry, currently serving as Senior Director of Clinical Science at Tonix Pharmaceuticals since January 2021, following roles as Director and Senior Scientist. Prior to this, David held the position of Assistant Professor of Psychiatry at Stony Brook University Health Sciences Center School of Medicine from November 2014 to December 2020. David's academic career also includes a tenure as Research Assistant Professor and Research Investigator at the University of Michigan Medical School from September 2006 to October 2014, as well as a postdoctoral researcher at both Washington University School of Medicine in St. Louis and the University of Michigan. David earned a PhD in Psychology with a neuroscience emphasis from the University of Wisconsin-Madison and holds a Bachelor's degree in Biology and Psychology from Rutgers University–New Brunswick.
This person is not in any teams
This person is not in any offices
Tonix Pharmaceuticals
Tonix is developing innovative pharmaceutical products to address major public health challenges. In addition to Tonmya for PTSD, Tonix is developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (Investigational New Drug) application stage, designed as a daytime treatment for PTSD, and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage, to be developed as a potential smallpox-preventing vaccine.